Stay updated with breaking news from Jim Simons. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
On May 10, 2023, Renaissance Technologies, led by renowned investor Jim Simons (Trades, Portfolio), made a notable addition to its investment portfolio by acquiring 3,966,024 shares of US Silica Holdings Inc (NYSE:SLCA). This transaction reflects a 12.30% change from the previous holding, with an additional 434,316 shares purchased at a trade price of $12.73.
On December 29, 2023, Renaissance Technologies, led by Jim Simons (Trades, Portfolio), made a notable adjustment to its investment portfolio by reducing its stake in Rocky Mountain Chocolate Factory Inc (NASDAQ:RMCF). Jim Simons (Trades, Portfolio), the founder of Renaissance Technologies Corporation, has been a prominent figure in the investment world since 1982.
On December 29, 2023, Renaissance Technologies, led by Jim Simons (Trades, Portfolio), made a notable addition to its investment portfolio by acquiring 30,305 shares of Culp Inc (NYSE:CULP), a company specializing in the manufacture and marketing of mattress and upholstery fabrics. The transaction was executed at a trade price of $5.79 per share, resulting in a total holding of 703,322 shares in the company. Despite the trade's seemingly modest impact on the overall portfolio, with a position size of 0.01% and a 5.64% stake in the traded stock, this move reflects a strategic investment ...
On December 29, 2023, Renaissance Technologies, led by Jim Simons (Trades, Portfolio), expanded its investment portfolio by adding shares of Ituran Location and Control Ltd (NASDAQ:ITRN). The firm acquired 16,100 shares at a trade price of $27.24.
Renowned investment firm Renaissance Technologies, led by Jim Simons (Trades, Portfolio), has recently increased its stake in Corcept Therapeutics Inc (NASDAQ:CORT), a pharmaceutical company specializing in the treatment of severe metabolic, oncologic, and neuropsychiatric disorders. This transaction underscores the firm's confidence in Corcept Therapeutics, even as it navigates the volatile biotechnology sector.